246 related articles for article (PubMed ID: 31018160)
1. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Song W; Jeong JY; Jeon HG; Seo SI; Jeon SS; Choi HY; Lee HM; Sung HH
Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
3. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
[TBL] [Abstract][Full Text] [Related]
4. Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis.
Chung HS; Hwang EC; Kim MS; Yu SH; Jung SI; Kang TW; Choi C; Choi SH; Kwon TG; Noh JH; Kim MK; Cho WJ; Kang SG; Kang SH; Cheon J; Seo IY; Chung H; Kim HS; Lee CH; Ku JY; Ha HK; Kim BH; Jeong CW; Ku JH; Kwak C; Kwon D
Clin Genitourin Cancer; 2019 Jun; 17(3):e394-e407. PubMed ID: 30782419
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Li H; Zhou J; Chen R; Zhu J; Wang J; Wen R
Urol Oncol; 2023 Aug; 41(8):356.e1-356.e9. PubMed ID: 37331821
[TBL] [Abstract][Full Text] [Related]
6. Impact of histologic variants on the oncological outcomes of patients with upper urinary tract cancers treated with radical surgery: a multi-institutional retrospective study.
Murakami Y; Matsumoto K; Ikeda M; Hirayama T; Utsunomiya T; Koguchi D; Matsuda D; Okuno N; Taoka Y; Irie A; Iwamura M
Int J Clin Oncol; 2019 Nov; 24(11):1412-1418. PubMed ID: 31197556
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Preoperative Albumin-Globulin Ratio on Oncologic Outcomes in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Xu H; Tan P; Ai J; Huang Y; Lin T; Yang L; Wei Q
Clin Genitourin Cancer; 2018 Oct; 16(5):e1059-e1068. PubMed ID: 29980449
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of Neutrophil-to-lymphocyte Ratio-based Markers During Pre- and Postadjuvant Chemotherapy in Patients With Advanced Urothelial Carcinoma of Upper Urinary Tract.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Clin Genitourin Cancer; 2017 Aug; 15(4):e633-e643. PubMed ID: 28174011
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
Yafi FA; Tanguay S; Rendon R; Jacobsen N; Fairey A; Izawa J; Kapoor A; Black P; Lacombe L; Chin J; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Kassouf W
Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
11. Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
Veeratterapillay R; Geraghty R; Pandian R; Roy C; Stenhouse G; Bird C; Soomro N; Paez E; Rogers A; Johnson M; Page T; Rix D; Thomas D; Rai BP
BJU Int; 2022 Jun; 129(6):744-751. PubMed ID: 34726325
[TBL] [Abstract][Full Text] [Related]
12. [Prospective controlled observation ofeffect of adjuvant chemotherapy onsurvival and prognosis ofhigh-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy].
Luo Y; Feng BF; Wei DC; Han YL; Li MC; Zhao JH; Lin YH; Li Q; Hou Z; Zhang GY; Jiang YG
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3158-3163. PubMed ID: 31694107
[No Abstract] [Full Text] [Related]
13. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
Seisen T; Krasnow RE; Bellmunt J; Rouprêt M; Leow JJ; Lipsitz SR; Vetterlein MW; Preston MA; Hanna N; Kibel AS; Sun M; Choueiri TK; Trinh QD; Chang SL
J Clin Oncol; 2017 Mar; 35(8):852-860. PubMed ID: 28045620
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A; Johnson M; Chester J; Jones R; Dolling D; Bryan RT; Harris C; Winterbottom A; Blacker A; Catto JWF; Chakraborti P; Donovan JL; Elliott PA; French A; Jagdev S; Jenkins B; Keeley FX; Kockelbergh R; Powles T; Wagstaff J; Wilson C; Todd R; Lewis R; Hall E
Lancet; 2020 Apr; 395(10232):1268-1277. PubMed ID: 32145825
[TBL] [Abstract][Full Text] [Related]
16. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
[TBL] [Abstract][Full Text] [Related]
17. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.
Kang HW; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YD; Ha YS; Kim TH; Kwon TG; Byun SS; Jeh SU; Kim WJ
J Korean Med Sci; 2017 Feb; 32(2):335-342. PubMed ID: 28049247
[TBL] [Abstract][Full Text] [Related]
18. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
[TBL] [Abstract][Full Text] [Related]
19. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
